Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Sunday, Longboard Pharmaceuticals Reports Interim Results From Phase 1b/2a PACIFIC Study, Showing 57.7% Seizure Reduction In DEE Patients

Author: Benzinga Newsdesk | September 09, 2024 03:51am

Bexicaserin achieved an overall median seizure reduction of 57.7% in countable motor seizures over an approximate 9-month treatment period
Favorable safety and tolerability results continue to be observed
Data to be presented at the 15th European Epilepsy Congress in Rome, Italy
Full 12-month OLE dataset expected early next year

Posted In: LBPH